CTIX Alerts 11/08/2014 17:50:08 $CTIX
>>"Another tumor marker, CEA, was decreased and the tumor size remained stable over 4 months in a pancreatic carcinoma patient...."
I missed the above the first few times I saw the whole release. The above data point is from doses <210 mg/m2. There is now data at 210 and hopefully 350.
That is a stage 4 pancreatic cancer with a prognosis of 6 months to a year. The tumor size stabilized for 4 months would be considered a breakthrough treatment if confirmed in more patients of that tumor type. If K stabilizes growth for a cancer for which there is no other effective treatment, it will be approved as a stand alone cancer drug.
K - CTIX - Old SA article
http://m.seekingalpha.com/article/1422381-cel...ved?page=2
An old seeking alpha very informative article on Kevetrin and CTIX.
This is the article that made me invest more in CTIX some 1 1/2 years back.
We have come a long way and Kevetrin has progressed further - to C9. Hoping that some of the things said in that article come true.
The comments and the debate on this article also gives a lot of info
Cellceutix Corporation: The Next Generation Of Cancer Tr...
For decades, humanity has fought the war against cancer with a shared common purpose and a mutual hope for victory over an advanced and constantly evolving enem...
View on seekingalpha.com
Preview by Yahoo
You can add me as an honorary member to the family and I'd be ....honored of course.
Yes we can all agree that CTIX has a lot good going on. Invest heavily and be unimaginably rewarded.
Thanks for the response.
Thanks Dr J, that explained a lot for me.
Personally I am encouraged by these low-dose results, but given the low sample size and that the nature of cancer pathology is that it can wax and wane on its own, I can draw no conclusions on efficacy. Thank goodness for the scientific process of drug trials: it's what Phase 2 and 3 trials are for!
Gee, one monsta whale among others come to mind and it's certainly not me.............................where's biohedge?
Yes George is dangerously definitive even in the face of contradicting statements from the company itself and from the resident docs on this board. Time will tell and it is not in his financial interest to be completely correct. (Which is the only reason I have some minuscule remnant of respect for his opinion.)
Nice!
I've got 4 ophthalmic surgeons in the immediate family and all three of them have bought into CTIX. They're very enthusiastic about B-Ocular, along with everything else. (FWIW the pediatrician and the oncology nurse practitioner are in, too. Oh, and the Morgan Stanley private wealth manager
God Bless you, I'll tell her tonight about your Cellceutix thoughts as we celebrate the Sabbath, she'll like that, a divine appointment........................All the best to you and yours, Shalom.
Thanks Citrati. I think TA can have temporary validity if enough people in the market agree on a 'trend' and trade accordingly. But it has been mathematically proven that such a phenomenon would not be sustainable, just as a cartel or a ponzi scheme or a Martingale system for roulette is not sustainable; it will ultimately fail. And note just the onerous initial conditionality: first you have to assume everyone agrees on the TA pattern. Open up 10 newspapers and find 10 horoscopes for Libra. Ever notice none of them are the same?
And to push any remaining doubt aside: Do you buy CTIX because it is in a channel? Or an inverted flag pattern, or head and shoulder or whatever? Or because you assessed its potential future free cash flows and thought it is still undervalued?
Finally: all the successful investors you can name are fundamental analysts, not TA's. There is a reason for that.
I look at CTIX's stock chart. I absolutely do. And I knew CTIX would have a pullback. Of course it will. And it will again many, many times. But what I do not know, and no one here knows either, is when and how much.
Having a cancer cure / stabilization / reduction will bring so many good feelings to those who have cancer, and their loved ones-priceless-and it will be reflected in the stock price.
I live in the doghouse around here. And sometimes I think she loves Leo more than me, LOL. Seriously, she loved the letter to Shareholders but other than that she only follows what I share, PR's. Her sister passed from breast cancer at a very early age, and she wants and prays for a miracle cure/drug for others in her heart. She prays Cellceutix will achieve it. From 1.75, the law was laid, "Don't ever sell my shares, it will be a heritage for my sister, I have the faith" and the rest is history......................................Shalom.
I am pretty sure we will get a PR regarding Leo's trip on Monday. Something has to be important enough for Leo to go to India for two weeks. As others have pointed out, the purpose was to meet with Dr. Reddy's about the formulation of B-Ocular and B-Otic. The timing is about right since the agreement was signed about nine months ago.
George is wrong about Kevetrin
Once the MTD is established, the trial will enroll another 12 patients who meet the criteria and will look for at least 1 out of 6 to determine if any grade 3 or 4 adverse effects are observed.
If they can reproduce this the trial will be declared over.
Once the trial is complete it could take several months of data analysis to declare primary and secondary out comes.
It would appear after 9 cohorts and 17 months that MTD has not been reached and that at doses of 350 mg/m2 Kevetrin is safe,
Our New COO has commented that he feels at least 2 mid phase trials will be created for Kevetrin and based on Leo's excitement I believe it will be for 1. stromal ovarian cancers refractory to cis platinin and 2. pancreatic cancer.
The reason the COO may have chosen these 2 cancers is based on Dana Farber data to date and by the fact that there are no current treatment options for these cancers.
By following this path Leo can seek orphan drug status for Kevetrin and the financial benefits the FDA will bestow upon CTIX.
Kevetrin if you recall is the golden goose for CTIX not Brilacidin which has been in the lime light of late.
Disingenuous as always, george.
Your "facts" are nothing more than your opinions which you never preface as such.
Why can't you acknowledge that a functional K, regardless as a single agent or in combo, would be an absolute home run?
Thought I ignored you already but guess I'll have to do it again. Hopefully everyone else does as well. Thus far you've served virtually no purpose here other than regurgitating the same OPINIONS on the daily.
I think I'll stick with CTIX COO Dr. James Alexander since he is a more credible source:
Quote:
. I believe the safety profile of Kevetrin has been very well evaluated in the current trial and is reassuring when Kevetrin is used a single agent and potentially in combination with other therapy.
I think you may be reading things a bit differently from what was intended. I have to admit there is some ambiguity in the quote. Allow me to edit the quote based on how I think it was intended. I added some explanatory phrases in parentheses.
"through the first eight cohorts, the preliminary data has been very encouraging, including one ovarian stromal carcinoma patient completing 7 dosing cycles. CA-125, an ovarian cancer marker, was also stabilized in some patients. (we have very limited data so far at higher doses)
(From the first 4 cohorts we saw) The biomarker p21 increased in 6 of 14 patients at relatively low doses of Kevetrin and we expect a higher percentage of p21 expression when the data (from the second 4 cohorts) is evaluated.
Another tumor marker, CEA, was decreased and the tumor size remained stable over 4 months in a pancreatic carcinoma patient...."
Your posts are unfair to everyone that doesn't know any better than the fact this is the exact same comments and facts you have used for over 6 months. And even your facts are starting to be twisted in with your opinion. But it's ok, everyone is entitled to their OPINION!
Kevetrin will be used as a single agent in some situations as stated by others much closer and more educated to what is actually going on. In my opinion!
GLTA
Hot Stocks to Follow for Investment Opportunity & Special Profile "InvestorsHub NewsWire" - 11/6/2014 6:00:00 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 10/30/2014 4:31:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2014 6:04:28 AM
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/24/2014 3:48:22 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/15/2014 1:50:04 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 9/4/2014 4:14:23 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/2/2014 6:29:26 AM
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant "Marketwired" - 6/23/2014 7:00:00 AM
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort "Marketwired" - 6/16/2014 7:00:00 AM
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol "Marketwired" - 6/2/2014 7:00:00 AM
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities "Marketwired" - 5/27/2014 7:00:00 AM
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market "Marketwired" - 5/19/2014 7:00:00 AM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 5/16/2014 11:57:54 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/12/2014 10:12:29 AM
Cellceutix Confident in Its Formidable Antibiotic Arsenal "Marketwired" - 5/12/2014 7:00:00 AM
Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis "Marketwired" - 5/5/2014 9:53:20 AM
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae "Marketwired" - 4/14/2014 6:30:00 AM
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid "Marketwired" - 4/1/2014 8:00:00 AM
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI "Marketwired" - 3/31/2014 9:25:00 AM
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis "Marketwired" - 3/25/2014 6:00:00 AM
Cellceutix to Initiate Psoriasis Clinical Trial "Marketwired" - 3/21/2014 6:00:00 AM
Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors "Marketwired" - 3/19/2014 8:40:37 AM
Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial "Marketwired" - 3/10/2014 6:00:00 AM
Cellceutix Expands to Gram-Negative Bacterial Infections "Marketwired" - 3/5/2014 6:00:00 AM
>>"Another tumor marker, CEA, was decreased and the tumor size remained stable over 4 months in a pancreatic carcinoma patient...."
I missed the above the first few times I saw the whole release. The above data point is from doses <210 mg/m2. There is now data at 210 and hopefully 350.
That is a stage 4 pancreatic cancer with a prognosis of 6 months to a year. The tumor size stabilized for 4 months would be considered a breakthrough treatment if confirmed in more patients of that tumor type. If K stabilizes growth for a cancer for which there is no other effective treatment, it will be approved as a stand alone cancer drug.
K - CTIX - Old SA article
http://m.seekingalpha.com/article/1422381-cel...ved?page=2
An old seeking alpha very informative article on Kevetrin and CTIX.
This is the article that made me invest more in CTIX some 1 1/2 years back.
We have come a long way and Kevetrin has progressed further - to C9. Hoping that some of the things said in that article come true.
The comments and the debate on this article also gives a lot of info
Cellceutix Corporation: The Next Generation Of Cancer Tr...
For decades, humanity has fought the war against cancer with a shared common purpose and a mutual hope for victory over an advanced and constantly evolving enem...
View on seekingalpha.com
Preview by Yahoo
You can add me as an honorary member to the family and I'd be ....honored of course.
Yes we can all agree that CTIX has a lot good going on. Invest heavily and be unimaginably rewarded.
Thanks for the response.
Thanks Dr J, that explained a lot for me.
Personally I am encouraged by these low-dose results, but given the low sample size and that the nature of cancer pathology is that it can wax and wane on its own, I can draw no conclusions on efficacy. Thank goodness for the scientific process of drug trials: it's what Phase 2 and 3 trials are for!
Gee, one monsta whale among others come to mind and it's certainly not me.............................where's biohedge?
Yes George is dangerously definitive even in the face of contradicting statements from the company itself and from the resident docs on this board. Time will tell and it is not in his financial interest to be completely correct. (Which is the only reason I have some minuscule remnant of respect for his opinion.)
Nice!
I've got 4 ophthalmic surgeons in the immediate family and all three of them have bought into CTIX. They're very enthusiastic about B-Ocular, along with everything else. (FWIW the pediatrician and the oncology nurse practitioner are in, too. Oh, and the Morgan Stanley private wealth manager
God Bless you, I'll tell her tonight about your Cellceutix thoughts as we celebrate the Sabbath, she'll like that, a divine appointment........................All the best to you and yours, Shalom.
Thanks Citrati. I think TA can have temporary validity if enough people in the market agree on a 'trend' and trade accordingly. But it has been mathematically proven that such a phenomenon would not be sustainable, just as a cartel or a ponzi scheme or a Martingale system for roulette is not sustainable; it will ultimately fail. And note just the onerous initial conditionality: first you have to assume everyone agrees on the TA pattern. Open up 10 newspapers and find 10 horoscopes for Libra. Ever notice none of them are the same?
And to push any remaining doubt aside: Do you buy CTIX because it is in a channel? Or an inverted flag pattern, or head and shoulder or whatever? Or because you assessed its potential future free cash flows and thought it is still undervalued?
Finally: all the successful investors you can name are fundamental analysts, not TA's. There is a reason for that.
I look at CTIX's stock chart. I absolutely do. And I knew CTIX would have a pullback. Of course it will. And it will again many, many times. But what I do not know, and no one here knows either, is when and how much.
Having a cancer cure / stabilization / reduction will bring so many good feelings to those who have cancer, and their loved ones-priceless-and it will be reflected in the stock price.
I live in the doghouse around here. And sometimes I think she loves Leo more than me, LOL. Seriously, she loved the letter to Shareholders but other than that she only follows what I share, PR's. Her sister passed from breast cancer at a very early age, and she wants and prays for a miracle cure/drug for others in her heart. She prays Cellceutix will achieve it. From 1.75, the law was laid, "Don't ever sell my shares, it will be a heritage for my sister, I have the faith" and the rest is history......................................Shalom.
I am pretty sure we will get a PR regarding Leo's trip on Monday. Something has to be important enough for Leo to go to India for two weeks. As others have pointed out, the purpose was to meet with Dr. Reddy's about the formulation of B-Ocular and B-Otic. The timing is about right since the agreement was signed about nine months ago.
George is wrong about Kevetrin
Once the MTD is established, the trial will enroll another 12 patients who meet the criteria and will look for at least 1 out of 6 to determine if any grade 3 or 4 adverse effects are observed.
If they can reproduce this the trial will be declared over.
Once the trial is complete it could take several months of data analysis to declare primary and secondary out comes.
It would appear after 9 cohorts and 17 months that MTD has not been reached and that at doses of 350 mg/m2 Kevetrin is safe,
Our New COO has commented that he feels at least 2 mid phase trials will be created for Kevetrin and based on Leo's excitement I believe it will be for 1. stromal ovarian cancers refractory to cis platinin and 2. pancreatic cancer.
The reason the COO may have chosen these 2 cancers is based on Dana Farber data to date and by the fact that there are no current treatment options for these cancers.
By following this path Leo can seek orphan drug status for Kevetrin and the financial benefits the FDA will bestow upon CTIX.
Kevetrin if you recall is the golden goose for CTIX not Brilacidin which has been in the lime light of late.
Disingenuous as always, george.
Your "facts" are nothing more than your opinions which you never preface as such.
Why can't you acknowledge that a functional K, regardless as a single agent or in combo, would be an absolute home run?
Thought I ignored you already but guess I'll have to do it again. Hopefully everyone else does as well. Thus far you've served virtually no purpose here other than regurgitating the same OPINIONS on the daily.
I think I'll stick with CTIX COO Dr. James Alexander since he is a more credible source:
Quote:
. I believe the safety profile of Kevetrin has been very well evaluated in the current trial and is reassuring when Kevetrin is used a single agent and potentially in combination with other therapy.
I think you may be reading things a bit differently from what was intended. I have to admit there is some ambiguity in the quote. Allow me to edit the quote based on how I think it was intended. I added some explanatory phrases in parentheses.
"through the first eight cohorts, the preliminary data has been very encouraging, including one ovarian stromal carcinoma patient completing 7 dosing cycles. CA-125, an ovarian cancer marker, was also stabilized in some patients. (we have very limited data so far at higher doses)
(From the first 4 cohorts we saw) The biomarker p21 increased in 6 of 14 patients at relatively low doses of Kevetrin and we expect a higher percentage of p21 expression when the data (from the second 4 cohorts) is evaluated.
Another tumor marker, CEA, was decreased and the tumor size remained stable over 4 months in a pancreatic carcinoma patient...."
Your posts are unfair to everyone that doesn't know any better than the fact this is the exact same comments and facts you have used for over 6 months. And even your facts are starting to be twisted in with your opinion. But it's ok, everyone is entitled to their OPINION!
Kevetrin will be used as a single agent in some situations as stated by others much closer and more educated to what is actually going on. In my opinion!
GLTA
Hot Stocks to Follow for Investment Opportunity & Special Profile "InvestorsHub NewsWire" - 11/6/2014 6:00:00 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 10/30/2014 4:31:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2014 6:04:28 AM
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/24/2014 3:48:22 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/15/2014 1:50:04 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 9/4/2014 4:14:23 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/2/2014 6:29:26 AM
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant "Marketwired" - 6/23/2014 7:00:00 AM
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort "Marketwired" - 6/16/2014 7:00:00 AM
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol "Marketwired" - 6/2/2014 7:00:00 AM
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities "Marketwired" - 5/27/2014 7:00:00 AM
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market "Marketwired" - 5/19/2014 7:00:00 AM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 5/16/2014 11:57:54 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/12/2014 10:12:29 AM
Cellceutix Confident in Its Formidable Antibiotic Arsenal "Marketwired" - 5/12/2014 7:00:00 AM
Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis "Marketwired" - 5/5/2014 9:53:20 AM
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae "Marketwired" - 4/14/2014 6:30:00 AM
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid "Marketwired" - 4/1/2014 8:00:00 AM
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI "Marketwired" - 3/31/2014 9:25:00 AM
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis "Marketwired" - 3/25/2014 6:00:00 AM
Cellceutix to Initiate Psoriasis Clinical Trial "Marketwired" - 3/21/2014 6:00:00 AM
Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors "Marketwired" - 3/19/2014 8:40:37 AM
Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial "Marketwired" - 3/10/2014 6:00:00 AM
Cellceutix Expands to Gram-Negative Bacterial Infections "Marketwired" - 3/5/2014 6:00:00 AM
